345(top 1%)
PR articles
37.0K(top 0.1%)
PR citations
100(top 0.1%)
PR h-index
108(top 0.1%)
h-index
394
documents
53.1K
doc citations
4.1K
citing journals
100
times ranked

Publications

350 PR articles • 39,125 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Catecholamine Dysregulation in Former American Football Players
Neurology, 2025, 104,
1.00Citations (PDF)
2Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity
JAMA - Journal of the American Medical Association, 2025, 334, 229
16.625Citations (PDF)
3Plasma p‐tau231 in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross‐sectional and longitudinal cohort study
Alzheimer's and Dementia, 2025, 21,
0.50Citations (PDF)
4Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease
JAMA Neurology, 2025, 82, 848
17.62Citations (PDF)
5Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies known and novel cross-population and ancestry-specific associations as novel risk loci for Alzheimer’s disease
Genome Biology, 2025, 26,
8.15Citations (PDF)
6Accounting for white matter uptake improves between tracer agreement in amyloid PET
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2025, 17,
2.50Citations (PDF)
7Examination of parkinsonism in former elite American football players
Parkinsonism and Related Disorders, 2024, 120, 105903
2.65Citations (PDF)
8Association of Vascular Risk Factors and CSF and Imaging Biomarkers With White Matter Hyperintensities in Former American Football Players
Neurology, 2024, 102,
1.013Citations (PDF)
9Flortaucipir tau PET findings from former professional and college American football players in the DIAGNOSE CTE research project
Alzheimer's and Dementia, 2024, 20, 1827-1838
0.511Citations (PDF)
10Harmonizing florbetapir and PiB PET measurements of cortical Aβ plaque burden using multiple regions‐of‐interest and machine learning techniques: An alternative to the Centiloid approach
Alzheimer's and Dementia, 2024, 20, 2165-2172
0.57Citations (PDF)
11Inflammatory biomarkers for neurobehavioral dysregulation in former American football players: findings from the DIAGNOSE CTE Research Project
Journal of Neuroinflammation, 2024, 21,
9.011Citations (PDF)
12Clinical Outcomes and Tau Pathology in Retired Football Players
Neurology: Clinical Practice, 2024, 14,
2.05Citations (PDF)
13APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia
Nature, 2024, 628, 154-161
37.9363Citations (PDF)
14p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial
Nature Medicine, 2024, 30, 1761-1770
33.037Citations (PDF)
15Single cell transcriptomes and multiscale networks from persons with and without Alzheimer’s disease
Nature Communications, 2024, 15,
13.720Citations (PDF)
16MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population
JAMA Neurology, 2024, 81, 1051
17.64Citations (PDF)
17Cavum Septum Pellucidum in Former American Football Players
Neurology: Clinical Practice, 2024, 14,
2.07Citations (PDF)
18Repetitive Head Impacts and Perivascular Space Volume in Former American Football Players
JAMA Network Open, 2024, 7, e2428687
6.67Citations (PDF)
19Examination of plasma biomarkers of amyloid, tau, neurodegeneration, and neuroinflammation in former elite American football players
Alzheimer's and Dementia, 2024, 20, 7529-7546
0.59Citations (PDF)
20Heparin treatment is associated with a delayed diagnosis of Alzheimer’s dementia in electronic health records from two large United States health systems
Molecular Psychiatry, 2024, 30, 1461-1465
7.86Citations (PDF)
21Olfactory function is reduced in a subset of former elite American football players with traumatic encephalopathy syndrome
Chemical Senses, 2024, 49,
1.40Citations (PDF)
221‐ versus 2‐test criteria for cognitive impairment and associations with CSF and imaging markers in former American football players
Alzheimer's and Dementia, 2024, 20,
0.50Citations (PDF)
23Beyond Traditional Measures: Exploring Cognitive Intraindividual Variability in Traumatic Encephalopathy Syndrome
Alzheimer's and Dementia, 2024, 20,
0.50Citations (PDF)
24White matter hyperintensities in former American football players
Alzheimer's and Dementia, 2023, 19, 1260-1273
0.521Citations (PDF)
25Neuropsychological test performance of former American football players
Alzheimer's Research and Therapy, 2023, 15,
6.626Citations (PDF)
26Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults
Alzheimer's Research and Therapy, 2023, 15,
6.636Citations (PDF)
27Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
JAMA Neurology, 2023, 80, 614
17.635Citations (PDF)
28Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man
Nature Medicine, 2023, 29, 1243-1252
33.0161Citations (PDF)
29Association Between False Memories and Delusions in Alzheimer Disease
JAMA Psychiatry, 2023, 80, 700
12.43Citations (PDF)
30Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity
JAMA Neurology, 2023, 80, 1051
17.644Citations (PDF)
31Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer’s disease
Nature Communications, 2023, 14,
13.721Citations (PDF)
32Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project
Alzheimer's Research and Therapy, 2023, 15,
6.620Citations (PDF)
33Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease
JAMA Neurology, 2023, 80, 1353
17.671Citations (PDF)
34The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation
Nature Neuroscience, 2023, 26, 2104-2121
17.085Citations (PDF)
35A Computational Monte Carlo Simulation Strategy to Determine the Temporal Ordering of Abnormal Age Onset Among Biomarkers of Alzheimer's Disease
IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 2613-2622
2.914Citations (PDF)
36Limitations of clinical trial sample size estimate by subtraction of two measurements
Statistics in Medicine, 2022, 41, 1137-1147
1.75Citations (PDF)
37Design and Development of a Community-Based, Interdisciplinary, Collaborative Dementia Care Program
American Journal of Geriatric Psychiatry, 2022, 30, 651-660
1.78Citations (PDF)
38Studying APOE ɛ4 Allele Dose Effects with a Univariate Morphometry Biomarker
Journal of Alzheimer's Disease, 2022, 85, 1233-1250
2.61Citations (PDF)
39Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Alzheimer's and Dementia, 2022, 18, 2687-2698
0.536Citations (PDF)
40A neurodegenerative disease landscape of rare mutations in Colombia due to founder effects
Genome Medicine, 2022, 14,
9.633Citations (PDF)
41Deep learning-based brain transcriptomic signatures associated with the neuropathological and clinical severity of Alzheimer’s disease
Brain Communications, 2022, 4,
3.625Citations (PDF)
42Genetic Evidence Supporting a Causal Role of Depression in Alzheimer’s Disease
Biological Psychiatry, 2022, 92, 25-33
5.455Citations (PDF)
43Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease
JAMA Neurology, 2022, 79, 592
17.666Citations (PDF)
44White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer’s disease that emerge prior to dementia
Alzheimer's Research and Therapy, 2022, 14,
6.630Citations (PDF)
45Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia
Acta Neuropathologica, 2022, 144, 589-601
9.277Citations (PDF)
46Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition
JAMA Neurology, 2022, 79, 1025
17.621Citations (PDF)
47Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players
European Journal of Nuclear Medicine and Molecular Imaging, 2022, 50, 435-452
5.518Citations (PDF)
48Developing univariate neurodegeneration biomarkers with low-rank and sparse subspace decomposition
Medical Image Analysis, 2021, 67, 101877
10.513Citations (PDF)
49Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel
JAMA Neurology, 2021, 78, 102
17.6250Citations (PDF)
50PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers
NeuroImage: Clinical, 2021, 31, 102749
3.322Citations (PDF)
51Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: findings from the Colombia-Boston (COLBOS) biomarker study
Alzheimer's Research and Therapy, 2021, 13,
6.653Citations (PDF)
52Cortical thickness across the lifespan in a Colombian cohort with autosomal‐dominant Alzheimer's disease: A cross‐sectional study
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13,
2.55Citations (PDF)
53National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome
Neurology, 2021, 96, 848-863
1.0277Citations (PDF)
54Genetic control of the human brain proteome
American Journal of Human Genetics, 2021, 108, 400-410
6.593Citations (PDF)
55Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
JAMA Neurology, 2021, 78, 396
17.6241Citations (PDF)
56Brain proteome-wide association study implicates novel proteins in depression pathogenesis
Nature Neuroscience, 2021, 24, 810-817
17.0150Citations (PDF)
57Improved Prediction of Imminent Progression to Clinically Significant Memory Decline Using Surface Multivariate Morphometry Statistics and Sparse Coding
Journal of Alzheimer's Disease, 2021, 81, 209-220
2.67Citations (PDF)
58Predicting future cognitive decline with hyperbolic stochastic coding
Medical Image Analysis, 2021, 70, 102009
10.52Citations (PDF)
59Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE ɛ3/ɛ4 Carriers
Journal of Alzheimer's Disease, 2021, 81, 339-354
2.617Citations (PDF)
60Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
EMBO Molecular Medicine, 2021, 13,
7.1196Citations (PDF)
61Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort
JAMA Network Open, 2021, 4, e2121697
6.68Citations (PDF)
62Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure
Advanced Science, 2021, 8,
12.6156Citations (PDF)
63Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases
Frontiers in Neuroscience, 2021, 15,
2.720Citations (PDF)
64Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project
Alzheimer's Research and Therapy, 2021, 13,
6.670Citations (PDF)
65Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease
Nature Communications, 2021, 12,
13.786Citations (PDF)
66Positron emission tomography imaging of serotonin degeneration and beta-amyloid deposition in late-life depression evaluated with multi-modal partial least squares
Translational Psychiatry, 2021, 11,
5.226Citations (PDF)
67Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis
Nature Genetics, 2021, 53, 143-146
25.2345Citations (PDF)
68Tau‐Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease
Annals of Neurology, 2021, 90, 751-762
6.640Citations (PDF)
69Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
Translational Psychiatry, 2021, 11,
5.258Citations (PDF)
70Closer correlations between florbetapir PET measurements of amyloid plaque burden using a cerebral white matter reference region and Alzheimer’s disease‐related hypometabolism
Alzheimer's and Dementia, 2021, 17,
0.50Citations (PDF)
71Improved comparability between measurements of mean cortical amyloid plaque burden derived from different PET tracers using multiple regions‐of‐interest and machine learning
Alzheimer's and Dementia, 2021, 17,
0.51Citations (PDF)
72Associations between different FDG PET indices and clinical ratings in cognitively unimpaired older adults
Alzheimer's and Dementia, 2021, 17,
0.50Citations (PDF)
73Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer’s disease
Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 330-332
6.311Citations (PDF)
74Longitudinal white matter and cognitive development in pediatric carriers of the apolipoprotein ε4 allele
NeuroImage, 2020, 222, 117243
4.429Citations (PDF)
75Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer’s Disease and Cognitive Decline
Journal of Alzheimer's Disease, 2020, 78, 721-734
2.616Citations (PDF)
76Applying surface-based morphometry to study ventricular abnormalities of cognitively unimpaired subjects prior to clinically significant memory decline
NeuroImage: Clinical, 2020, 27, 102338
3.321Citations (PDF)
77Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
JAMA - Journal of the American Medical Association, 2020, 324, 772
16.61,230Citations (PDF)
78Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer’s Disease: Preliminary Findings from the Colombian Alzheimer’s Prevention Initiative Biomarker Study
Journal of Alzheimer's Disease, 2020, 77, 1743-1753
2.618Citations (PDF)
79Longitudinal data in peripheral blood confirms PM20D1 is a quantitative trait locus (QTL) for Alzheimer’s disease and implicates its dynamic role in disease progression
Alzheimer's and Dementia, 2020, 16,
0.50Citations (PDF)
80The Generation program: Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation study 1 and Generation study 2
Alzheimer's and Dementia, 2020, 16,
0.51Citations (PDF)
81Umibecestat in the API Generation program: Worsening in RBANS and/or CDR on treatment reverses after wash‐out
Alzheimer's and Dementia, 2020, 16,
0.56Citations (PDF)
82The API Generation program: Umibecestat treatment and discontinuation effects on hippocampal and whole brain volumes in the overall population and amyloid‐negative APOE4 homozygotes
Alzheimer's and Dementia, 2020, 16,
0.54Citations (PDF)
83The API Generation program: Biomarker phenotyping of cognitively unimpaired participants screened in Generation study 1 and Generation study 2
Alzheimer's and Dementia, 2020, 16,
0.52Citations (PDF)
84Longitudinal data in peripheral blood confirm that PM20D1 is a quantitative trait locus (QTL) for Alzheimer’s disease and implicate its dynamic role in disease progression
Clinical Epigenetics, 2020, 12,
3.927Citations (PDF)
85Effects of LDL Cholesterol and Statin Use on Verbal Learning and Memory in Older Adults at Genetic Risk for Alzheimer’s Disease
Journal of Alzheimer's Disease, 2020, 75, 903-910
2.65Citations (PDF)
86Effect of ApoE isoforms on mitochondria in Alzheimer disease
Neurology, 2020, 94,
1.0109Citations (PDF)
87Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study
Lancet Neurology, The, 2020, 19, 513-521
17.9140Citations (PDF)
88Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers
Neurology, 2020, 95,
1.08Citations (PDF)
89Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
Nature Medicine, 2020, 26, 379-386
33.01,042Citations (PDF)
90Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study
Nature Communications, 2020, 11,
13.7392Citations (PDF)
91APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Nature, 2020, 581, 71-76
37.91,042Citations (PDF)
92Computing Univariate Neurodegenerative Biomarkers with Volumetric Optimal Transportation: A Pilot Study
Neuroinformatics, 2020, 18, 531-548
2.64Citations (PDF)
93Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation
Nature Medicine, 2020, 26, 769-780
33.0872Citations (PDF)
94Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer’s disease dementia
PLoS ONE, 2020, 15, e0231720
2.337Citations (PDF)
95Long-Term Physical Exercise and Mindfulness Practice in an Aging Population
Frontiers in Psychology, 2020, 11,
2.224Citations (PDF)
96Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease
JAMA Neurology, 2019, 76, 1219
17.6138Citations (PDF)
97Common BACE2 Polymorphisms are Associated with Altered Risk for Alzheimer’s Disease and CSF Amyloid Biomarkers in APOE ε4 Non-Carriers
Scientific Reports, 2019, 9,
3.423Citations (PDF)
98Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease
PLoS ONE, 2019, 14, e0217566
2.353Citations (PDF)
99Applying surface-based hippocampal morphometry to study APOE-E4 allele dose effects in cognitively unimpaired subjects
NeuroImage: Clinical, 2019, 22, 101744
3.346Citations (PDF)
100Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age
Nature Communications, 2019, 10,
13.7202Citations (PDF)
101Tau Positron-Emission Tomography in Former National Football League Players
New England Journal of Medicine, 2019, 380, 1716-1725
34.6197Citations (PDF)
102Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD
Acta Neuropathologica, 2019, 137, 879-899
9.2123Citations (PDF)
103Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing
Nature Genetics, 2019, 51, 414-430
25.22,782Citations (PDF)
104IC‐P‐173: INDIVIDUAL‐BASED NETWORK ANALYSIS: A NOVEL APPROACH TO INVESTIGATE THE PATHOLOGICAL SPREAD OF PHF TAU USING GRAPH THEORY IN CLINICAL AND PRECLINICAL STAGES OF ALZHEIMER'S DISEASE
Alzheimer's and Dementia, 2019, 15,
0.50Citations (PDF)
105IC‐P‐009: COMPARISON OF CROSS‐SECTIONAL AND LONGITUDINAL FREESURFER PIPELINE FOR ESTIMATION OF FLORBETAPIR PET SUVR MEASUREMENTS
Alzheimer's and Dementia, 2019, 15,
0.50Citations (PDF)
106IC‐P‐111: IMPACT OF CEREBRAL ISCHEMIA SCORES, FIBRILLAR AMYLOID‐B BURDEN AND AGE ON WHITE MATTER HYPERINTENSITY VOLUMES IN COGNITIVELY UNIMPAIRED OLDER ADULT APOE4 CARRIERS AND NON‐CARRIERS
Alzheimer's and Dementia, 2019, 15,
0.50Citations (PDF)
107Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report
Nature Medicine, 2019, 25, 1680-1683
33.0525Citations (PDF)
108A concise and persistent feature to study brain resting‐state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative
Human Brain Mapping, 2019, 40, 1062-1081
3.532Citations (PDF)
109Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease
JAMA Neurology, 2018, 75, 548
17.6169Citations (PDF)
110Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study
Lancet Neurology, The, 2018, 17, 548-558
17.9123Citations (PDF)
111Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer’s Disease Related Brain Regions
Journal of Alzheimer's Disease, 2018, 62, 833-840
2.612Citations (PDF)
112IC‐P‐026: QUANTIFICATION OF AMYLOID BURDEN FROM FLORBETAPIR PET IMAGES WITHOUT USING TARGET AND REFERENCE REGIONS: PRELIMINARY FINDINGS BASED ON THE DEEP LEARNING 3D CONVOLUTIONAL NEURAL NETWORK APPROACH
Alzheimer's and Dementia, 2018, 14,
0.50Citations (PDF)
113IC‐P‐106: FLORTAUCIPIR PAIRED HELICAL FILAMENT TAU BURDEN AND CORRELATION WITH COGNITIVE DECLINE IN MCI PATIENTS WITHOUT Aβ
Alzheimer's and Dementia, 2018, 14,
0.50Citations (PDF)
114IC‐P‐025: FEASIBILITY OF QUANTIFYING AMYLOID BURDEN USING VOLUMETRIC MRI DATA: PRELIMINARY FINDINGS BASED ON THE DEEP LEARNING 3D CONVOLUTIONAL NEURAL NETWORK APPROACH
Alzheimer's and Dementia, 2018, 14,
0.50Citations (PDF)
115IC‐P‐010: COMPARING CEREBRAL WHITE MATTER, CEREBELLAR, AND PONTINE REFERENCE REGIONS TO CHARACTERIZE FLORBETAPIR PET MEASUREMENTS OF AMYLOID‐β BURDEN IN PSEN1 E280A MUTATION CARRIERS AND NONCARRIERS FROM THE COLOMBIAN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE KINDRED
Alzheimer's and Dementia, 2018, 14,
0.50Citations (PDF)
116O3‐04‐02: FLORTAUCIPIR PAIRED HELICAL FILAMENT TAU BURDEN AND CORRELATION WITH COGNITIVE DECLINE IN MCI PATIENTS WITHOUT ANY Aβ
Alzheimer's and Dementia, 2018, 14,
0.50Citations (PDF)
117IC‐P‐003: RELATIONSHIPS BETWEEN MEAN CORTICAL AMYLOID BURDEN AND REGIONAL GRAY MATTER REDUCTIONS IN ALZHEIMER'S DEMENTIA, MILD COGNITIVE IMPAIRMENT AND UNIMPAIRED OLDER ADULTS
Alzheimer's and Dementia, 2018, 14,
0.50Citations (PDF)
118P2‐071: COMPARING CEREBRAL WHITE MATTER, CEREBELLAR, AND PONTINE REFERENCE REGIONS TO CHARACTERIZE FLORBETAPIR PET MEASUREMENTS OF AMYLOID‐β BURDEN IN PSEN1 E280A MUTATION CARRIERS AND NONCARRIERS FROM THE COLOMBIAN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE KINDRED
Alzheimer's and Dementia, 2018, 14,
0.50Citations (PDF)
119P2‐073: FEASIBILITY OF QUANTIFYING AMYLOID BURDEN USING VOLUMETRIC MRI DATA: PRELIMINARY FINDINGS BASED ON THE DEEP LEARNING 3D CONVOLUTIONAL NEURAL NETWORK APPROACH
Alzheimer's and Dementia, 2018, 14,
0.50Citations (PDF)
120Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus
Neuron, 2018, 99, 64-82.e7
11.0693Citations (PDF)
121Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET
Journal of Alzheimer's Disease, 2018, 63, 603-615
2.614Citations (PDF)
122The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target
Brain, 2018, ,
8.437Citations (PDF)
123Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment
NeuroImage: Clinical, 2018, 20, 286-296
3.387Citations (PDF)
124Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism
Alzheimer's Research and Therapy, 2017, 9,
6.631Citations (PDF)
125Prevalence, Patterns, and Predictors of Depression Treatment among Community-Dwelling Elderly Individuals with Dementia in the United States
American Journal of Geriatric Psychiatry, 2017, 25, 803-813
1.717Citations (PDF)
126Subjective memory complaints in preclinical autosomal dominant Alzheimer disease
Neurology, 2017, 89, 1464-1470
1.026Citations (PDF)
127Multivariate analyses of peripheral blood leukocyte transcripts distinguish Alzheimer's, Parkinson's, control, and those at risk for developing Alzheimer's
Neurobiology of Aging, 2017, 58, 225-237
3.417Citations (PDF)
128Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease
Nature Genetics, 2017, 49, 1373-1384
25.2961Citations (PDF)
129[P4–247]: LEFT LATERALIZED CEREBRAL GLUCOSE METABOLISM DECLINES IN AMYLOID‐β‐POSITIVE SUBJECTS WITH MILD COGNITIVE IMPAIRMENT
Alzheimer's and Dementia, 2017, 13,
0.50Citations (PDF)
130[IC‐P‐210]: LEFT LATERALIZED CEREBRAL GLUCOSE METABOLISM DECLINES IN AMYLOID‐β– POSITIVE SUBJECTS WITH MILD COGNITIVE IMPAIRMENT
Alzheimer's and Dementia, 2017, 13,
0.50Citations (PDF)
131[P3–032]: SSRI USE ASSOCIATED WITH REDUCED AMYLOID BURDEN IN PERSONS WITH COMBAT‐RELATED PTSD: PRELIMINARY FINDINGS FROM ADNI‐DOD
Alzheimer's and Dementia, 2017, 13,
0.50Citations (PDF)
132[IC‐P‐041]: SAMPLE SIZES FOR 24‐MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID‐POSITIVE ADULTS
Alzheimer's and Dementia, 2017, 13,
0.50Citations (PDF)
133[IC‐P‐209]: CAVEATS WHEN SUBTRACTING TWO SERIAL MEASUREMENTS TO ESTIMATE THE NUMBER OF PARTICIPANTS NEEDED FOR CLINICAL TRIALS THAT ARE LONGER OR SHORTER THAN THE OBSERVED MEASUREMENT INTERVAL
Alzheimer's and Dementia, 2017, 13,
0.50Citations (PDF)
134[IC‐P‐211]: A COMPUTATIONAL MONTE CARLO SIMULATION STRATEGY TO COMPARE THE ONSET OF DIFFERENT BIOMARKER AND COGNITIVE CHANGES
Alzheimer's and Dementia, 2017, 13,
0.50Citations (PDF)
135[P1–260]: A COMPUTATIONAL MONTE‐CARLO SIMULATION STRATEGY TO COMPARE THE ONSET OF DIFFERENT BIOMARKER AND COGNITIVE CHANGES
Alzheimer's and Dementia, 2017, 13,
0.50Citations (PDF)
136[P1–434]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVITY IN THE DEFAULT MODE NETWORK IN AUTOSOMAL‐DOMINANT ALZHEIMER's DISEASE: A PRELIMINARY REPORT
Alzheimer's and Dementia, 2017, 13,
0.50Citations (PDF)
137[P2–333]: CAVEATS WHEN SUBTRACTING TWO SERIAL MEASUREMENTS TO ESTIMATE THE NUMBER OF PARTICIPANTS NEEDED FOR CLINICAL TRIALS THAT ARE LONGER OR SHORTER THAN THE OBSERVED MEASUREMENT INTERVAL
Alzheimer's and Dementia, 2017, 13,
0.50Citations (PDF)
138[O5–01–04]: SAMPLE SIZES FOR 24‐MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID‐POSITIVE ADULTS
Alzheimer's and Dementia, 2017, 13,
0.50Citations (PDF)
139Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
Frontiers in Aging Neuroscience, 2017, 9,
4.097Citations (PDF)
140APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts
PLoS Medicine, 2017, 14, e1002254
8.1149Citations (PDF)
141[P1–030]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVITY IN THE DEFAULT MODE NETWORK IN AUTOSOMAL‐DOMINANT ALZHEIMER's DISEASE: A PRELIMINARY REPORT
Alzheimer's and Dementia, 2017, 13,
0.50Citations (PDF)
142Upper-Extremity Dual-Task Function: An Innovative Method to Assess Cognitive Impairment in Older Adults
Frontiers in Aging Neuroscience, 2016, 8,
4.063Citations (PDF)
143A Triple Network Connectivity Study of Large-Scale Brain Systems in Cognitively Normal APOE4 Carriers
Frontiers in Aging Neuroscience, 2016, 8,
4.041Citations (PDF)
144Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group
PLoS ONE, 2016, 11, e0152082
2.351Citations (PDF)
145A Cross-Sectional Analysis of Late-Life Cardiovascular Factors and Their Relation to Clinically Defined Neurodegenerative Diseases
Alzheimer Disease and Associated Disorders, 2016, 30, 223-229
1.320Citations (PDF)
146The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer’s Disease
Journal of Alzheimer's Disease, 2016, 51, 345-356
2.684Citations (PDF)
147P1‐292: Lower Frontal Amyloid Burden in Antidepressant Users: Preliminary Findings From Persons With and Without Post‐Traumatic Stress Disorder in The ADNI DOD Study
2016, 12,
0Citations (PDF)
148P2‐243: Higher BMI is Associated with Greater Cerebral Glucose Metabolism in Late Middle‐Aged and Elderly Subjects Regardless of APOE ε4 Genotype
Alzheimer's and Dementia, 2016, 12,
0.50Citations (PDF)
149F4‐03‐04: The Alzheimer's Prevention Initiative
Alzheimer's and Dementia, 2016, 12,
0.51Citations (PDF)
150Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study
Neurobiology of Aging, 2016, 48, 122-134
3.459Citations (PDF)
151Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials
Alzheimer's and Dementia, 2016, 12, 631-632
0.534Citations (PDF)
152Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition
Journal of Neuropathology and Experimental Neurology, 2016, 75, 748-754
1.8125Citations (PDF)
153Ketones block amyloid entry and improve cognition in an Alzheimer's model
Neurobiology of Aging, 2016, 39, 25-37
3.4135Citations (PDF)
154Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease
JAMA Neurology, 2016, 73, 431
17.681Citations (PDF)
155A potential role for the midbrain in integrating fat‐free mass determined energy needs: An H215O PET study
Human Brain Mapping, 2015, 36, 2406-2415
3.520Citations (PDF)
156Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region
Journal of Nuclear Medicine, 2015, 56, 560-566
5.5148Citations (PDF)
157Rarity of the Alzheimer Disease–ProtectiveAPPA673T Variant in the United States
JAMA Neurology, 2015, 72, 209
17.647Citations (PDF)
158Association of Pituitary Adenylate Cyclase–Activating Polypeptide With Cognitive Decline in Mild Cognitive Impairment Due to Alzheimer Disease
JAMA Neurology, 2015, 72, 333
17.653Citations (PDF)
159Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program
Neuropathology, 2015, 35, 354-389
1.2459Citations (PDF)
160PL‐01‐01: What will it take to end Alzheimer's?
2015, 11,
0Citations (PDF)
161Disrupted Frontoparietal Network Mediates White Matter Structure Dysfunction Associated with Cognitive Decline in Hypertension Patients
Journal of Neuroscience, 2015, 35, 10015-10024
3.786Citations (PDF)
162The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015
Alzheimer's and Dementia, 2015, 11, 757-771
0.5277Citations (PDF)
163Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease
JAMA Neurology, 2015, 72, 912
17.6120Citations (PDF)
164Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred
JAMA Neurology, 2015, 72, 316
17.6169Citations (PDF)
165Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios
Journal of Nuclear Medicine, 2015, 56, 567-574
5.5345Citations (PDF)
166Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques
JAMA Neurology, 2015, 72, 1124
17.688Citations (PDF)
167Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease
Molecular Psychiatry, 2015, 20, 1294-1300
7.866Citations (PDF)
168Alzheimer's disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes
Neurobiology of Aging, 2015, 36, 583-591
3.4184Citations (PDF)
169Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry
NeuroImage, 2015, 104, 1-20
4.446Citations (PDF)
170CAP—advancing the evaluation of preclinical Alzheimer disease treatments
Nature Reviews Neurology, 2015, 12, 56-61
28.685Citations (PDF)
171A novel Alzheimer disease locus located near the gene encoding tau protein
Molecular Psychiatry, 2015, 21, 108-117
7.8306Citations (PDF)
172Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI
Alzheimer Disease and Associated Disorders, 2015, 29, 101-109
1.314Citations (PDF)
173The Alzheimer’s Prevention Initiative Composite Cognitive Test Score
Journal of Clinical Psychiatry, 2014, 75, 652-660
1.880Citations (PDF)
174Biochemical Assessment of Precuneus and Posterior Cingulate Gyrus in the Context of Brain Aging and Alzheimer’s Disease
PLoS ONE, 2014, 9, e105784
2.318Citations (PDF)
1752014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease
Alzheimer's and Dementia, 2014, 10,
0.567Citations (PDF)
176Pituitary adenylate cyclase–activating polypeptide is reduced in Alzheimer disease
Neurology, 2014, 82, 1724-1728
1.056Citations (PDF)
177Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias
PLoS Genetics, 2014, 10, e1004606
3.2344Citations (PDF)
178Neuropathologic Heterogeneity Does Not Impair Florbetapir-Positron Emission Tomography Postmortem Correlates
Journal of Neuropathology and Experimental Neurology, 2014, 73, 72-80
1.839Citations (PDF)
179Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease
JAMA Neurology, 2014, 71, 1394
17.6186Citations (PDF)
180Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity
Neurobiology of Aging, 2014, 35, 2064-2071
3.4101Citations (PDF)
181Brain glucose and acetoacetate metabolism: a comparison of young and older adults
Neurobiology of Aging, 2014, 35, 1386-1395
3.4125Citations (PDF)
182Brain Differences in Infants at Differential Genetic Risk for Late-Onset Alzheimer Disease
JAMA Neurology, 2014, 71, 11
17.6248Citations (PDF)
183Fibrillar amyloid correlates of preclinical cognitive decline
Alzheimer's and Dementia, 2014, 10,
0.515Citations (PDF)
184Symptom onset in autosomal dominant Alzheimer disease
Neurology, 2014, 83, 253-260
1.0487Citations (PDF)
185P4‐298: IMPROVING THE POWER TO TRACK FIBRILLAR AMYLOID PET MEASUREMENTS AND EVALUATE AMYLOID‐MODIFYING TREATMENTS USING A CEREBRAL WHITE MATTER REFERENCE REGION‐OF‐INTEREST
2014, 10,
0Citations (PDF)
186Disrupted Functional and Structural Networks in Cognitively Normal Elderly Subjects with the APOE ɛ4 Allele
Neuropsychopharmacology, 2014, 40, 1181-1191
5.366Citations (PDF)
187Endpoints in Preclinical Alzheimer’s Disease Trials
Journal of Clinical Psychiatry, 2014, 75, 661-662
1.86Citations (PDF)
188Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic Intervention
Journal of Alzheimer's Disease, 2013, 33, S405-S416
2.686Citations (PDF)
189Ushering in the study and treatment of preclinical Alzheimer disease
Nature Reviews Neurology, 2013, 9, 371-381
28.6134Citations (PDF)
190Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology
JAMA Neurology, 2013, 70, 1150
17.6160Citations (PDF)
191APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease
Neurobiology of Aging, 2013, 34, 1007-1017
3.473Citations (PDF)
192Overfeeding Over 24 Hours Does Not Activate Brown Adipose Tissue in Humans
Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1956-E1960
4.143Citations (PDF)
193The Receiver Operational Characteristic for Binary Classification with Multiple Indices and Its Application to the Neuroimaging Study of Alzheimer's Disease
IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2013, 10, 173-180
2.924Citations (PDF)
194Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease
Neurobiology of Aging, 2013, 34, 1-12
3.4233Citations (PDF)
195Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals
Neurobiology of Aging, 2013, 34, 822-831
3.4125Citations (PDF)
196A Sparse Structure Learning Algorithm for Gaussian Bayesian Network Identification from High-Dimensional Data
IEEE Transactions on Pattern Analysis and Machine Intelligence, 2013, 35, 1328-1342
11.256Citations (PDF)
197Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ε4 carriers
NeuroImage: Clinical, 2013, 2, 512-520
3.354Citations (PDF)
198O2–03–01: Validation of the Alzheimer's Prevention Initiative Composite Cognitive Test Score
2013, 9,
0Citations (PDF)
199Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions
Neurology, 2013, 80, 1557-1564
1.095Citations (PDF)
200Alzheimer's disease-related changes in regional spontaneous brain activity levels and inter-region interactions in the default mode network
Brain Research, 2013, 1509, 58-65
2.514Citations (PDF)
201A Genome-Wide Association Study of Depressive Symptoms
Biological Psychiatry, 2013, 73, 667-678
5.4162Citations (PDF)
202Fat-free body mass but not fat mass is associated with reduced gray matter volume of cortical brain regions implicated in autonomic and homeostatic regulation
NeuroImage, 2013, 64, 712-721
4.452Citations (PDF)
203Posterior Cingulate Glucose Metabolism, Hippocampal Glucose Metabolism, and Hippocampal Volume in Cognitively Normal, Late-Middle-Aged Persons at 3 Levels of Genetic Risk for Alzheimer Disease
JAMA Neurology, 2013, 70, 320
17.6151Citations (PDF)
204Effects of Memantine on Clinical Ratings, Fluorodeoxyglucose Positron Emission Tomography Measurements, and Cerebrospinal Fluid Assays in Patients With Moderate to Severe Alzheimer Dementia
Journal of Clinical Psychopharmacology, 2013, 33, 636-642
1.733Citations (PDF)
205Initial Assessment of the Pathogenic Mechanisms of the Recently Identified Alzheimer Risk Loci
Annals of Human Genetics, 2013, 77, 85-105
1.144Citations (PDF)
206Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers
Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 556-561
6.347Citations (PDF)
207Apolipoprotein E as a β-amyloid-independent factor in Alzheimer’s disease
Alzheimer's Research and Therapy, 2013, 5, 38
6.651Citations (PDF)
208Association between an Alzheimer’s Disease-Related Index and APOE ε4 Gene Dose
PLoS ONE, 2013, 8, e67163
2.313Citations (PDF)
209Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline
Neurology, 2012, 79, 1636-1644
1.0221Citations (PDF)
210Summary Metrics to Assess Alzheimer Disease–Related Hypometabolic Pattern with 18F-FDG PET: Head-to-Head Comparison
Journal of Nuclear Medicine, 2012, 53, 592-600
5.584Citations (PDF)
211A coding variant in CR1 interacts with APOE-ɛ4 to influence cognitive decline
Human Molecular Genetics, 2012, 21, 2377-2388
2.995Citations (PDF)
212Considerations in the Design of Clinical Trials for Cognitive Aging
Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2012, 67, 766-772
3.514Citations (PDF)
213Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study
Lancet Neurology, The, 2012, 11, 1048-1056
17.9501Citations (PDF)
214Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Lancet Neurology, The, 2012, 11, 669-678
17.9771Citations (PDF)
215Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons
Neurobiology of Aging, 2012, 33, 827.e11-827.e19
3.4124Citations (PDF)
216A genome-wide scan for common variants affecting the rate of age-related cognitive decline
Neurobiology of Aging, 2012, 33, 1017.e1-1017.e15
3.4196Citations (PDF)
217Gray matter network associated with risk for Alzheimer's disease in young to middle-aged adults
Neurobiology of Aging, 2012, 33, 2723-2732
3.488Citations (PDF)
218Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study
Lancet Neurology, The, 2012, 11, 1057-1065
17.9224Citations (PDF)
219Brain imaging in the study of Alzheimer's disease
NeuroImage, 2012, 61, 505-516
4.4121Citations (PDF)
220Postprandial plasma PYY concentrations are associated with increased regional gray matter volume and rCBF declines in caudate nuclei — A combined MRI and H215O PET study
NeuroImage, 2012, 60, 592-600
4.415Citations (PDF)
221Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: A cross-validation study using voxel-based multi-modal partial least squares
NeuroImage, 2012, 60, 2316-2322
4.437Citations (PDF)
222Analysis of Copy Number Variation in Alzheimer’s Disease in a Cohort of Clinically Characterized and Neuropathologically Verified Individuals
PLoS ONE, 2012, 7, e50640
2.352Citations (PDF)
223Attention‐related networks in Alzheimer's disease: A resting functional MRI study
Human Brain Mapping, 2012, 33, 1076-1088
3.5118Citations (PDF)
224Large-scale directional connections among multi resting-state neural networks in human brain: A functional MRI and Bayesian network modeling study
NeuroImage, 2011, 56, 1035-1042
4.452Citations (PDF)
225Association between GAB2 haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOEε4 carriers
NeuroImage, 2011, 54, 1896-1902
4.424Citations (PDF)
226Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease
Archives of Neurology, 2011, 68, 1404
6.8341Citations (PDF)
227Functional Links Between Aβ Toxicity, Endocytic Trafficking, and Alzheimer’s Disease Risk Factors in Yeast
Science, 2011, 334, 1241-1245
36.2371Citations (PDF)
228Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Neurobiology of Aging, 2011, 32, 1207-1218
3.4706Citations (PDF)
229Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments
Neurobiology of Aging, 2011, 32, S44-S47
3.431Citations (PDF)
230Characterizing Alzheimer's disease using a hypometabolic convergence index
NeuroImage, 2011, 56, 52-60
4.4154Citations (PDF)
231A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease
Journal of Alzheimer's Disease, 2011, 22, 1241-1256
2.699Citations (PDF)
232A method of generating image-derived input function in a quantitative 18F-FDG PET study based on the shape of the input function curve
Nuclear Medicine Communications, 2011, 32, 1121-1127
1.110Citations (PDF)
233Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
Nature Genetics, 2011, 43, 436-441
25.21,840Citations (PDF)
234CR1 is associated with amyloid plaque burden and age‐related cognitive decline
Annals of Neurology, 2011, 69, 560-569
6.6160Citations (PDF)
235Altered default mode network connectivity in alzheimer's disease—A resting functional MRI and bayesian network study
Human Brain Mapping, 2011, 32, 1868-1881
3.5192Citations (PDF)
236Positron Emission Tomography and Neuropathologic Estimates of Fibrillar Amyloid-β in a Patient With Down Syndrome and Alzheimer Disease
Archives of Neurology, 2011, 68, 1461
6.854Citations (PDF)
237Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Journal of Alzheimer's Disease, 2011, 26, 321-329
2.6316Citations (PDF)
238Clinical Impact of Updated Diagnostic and Research Criteria for Alzheimer’s Disease
Journal of Clinical Psychiatry, 2011, 72, e37
1.815Citations (PDF)
239High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation
BMC Genomics, 2010, 11,
3.374Citations (PDF)
240Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models
Brain Research, 2010, 1347, 179-185
2.596Citations (PDF)
241Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor‐based morphometry
Human Brain Mapping, 2010, 31, 499-514
3.572Citations (PDF)
242Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment
Journal of Neuroscience Methods, 2010, 192, 277-285
2.214Citations (PDF)
243Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions
Nature Genetics, 2010, 42, 234-239
25.2564Citations (PDF)
244Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the APOE ε4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene
Journal of Alzheimer's Disease, 2010, 22, 307-313
2.6144Citations (PDF)
245Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals
Human Molecular Genetics, 2010, 19, 3295-3301
2.9238Citations (PDF)
246Alzheimer's Prevention Initiative: A Proposal to Evaluate Presymptomatic Treatments as Quickly as Possible
Biomarkers in Medicine, 2010, 4, 3-14
1.5152Citations (PDF)
247Hypometabolism in Alzheimer-Affected Brain Regions in Cognitively Healthy Latino Individuals Carrying the Apolipoprotein E ε4 Allele
Archives of Neurology, 2010, 67,
6.896Citations (PDF)
248Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes
Archives of Neurology, 2010, 67, 1473
6.8402Citations (PDF)
249Mapping Alzheimer's disease progression in 1309 MRI scans: Power estimates for different inter-scan intervals
NeuroImage, 2010, 51, 63-75
4.486Citations (PDF)
250Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative
NeuroImage, 2010, 51, 654-664
4.4159Citations (PDF)
251Reducing modeling error of graphical methods for estimating volume of distribution measurements in PIB–PET study
Mathematical Biosciences, 2010, 226, 134-146
1.64Citations (PDF)
252Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology
Neurobiology of Aging, 2010, 31, 549-566
3.473Citations (PDF)
253Evidence for an association between KIBRA and late-onset Alzheimer's disease
Neurobiology of Aging, 2010, 31, 901-909
3.4106Citations (PDF)
254Whole brain atrophy rate predicts progression from MCI to Alzheimer’s disease
Neurobiology of Aging, 2010, 31, 1601-1605
3.448Citations (PDF)
255The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core
Alzheimer's and Dementia, 2010, 6, 221-229
0.5504Citations (PDF)
256Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging
NeuroImage, 2010, 49, 169-176
4.466Citations (PDF)
257Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation
NeuroImage, 2010, 50, 935-949
4.4315Citations (PDF)
258Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6820-6825
7.5754Citations (PDF)
259Improved application of independent component analysis to functional magnetic resonance imaging study via linear projection techniques
Human Brain Mapping, 2009, 30, 417-431
3.515Citations (PDF)
260FDG–PET parametric imaging by total variation minimization
Computerized Medical Imaging and Graphics, 2009, 33, 295-303
4.617Citations (PDF)
261Genetic Control of Human Brain Transcript Expression in Alzheimer Disease
American Journal of Human Genetics, 2009, 84, 445-458
6.5314Citations (PDF)
262Longitudinal Modeling of Age-Related Memory Decline and the APOEε4 Effect
New England Journal of Medicine, 2009, 361, 255-263
34.6521Citations (PDF)
263Reanalysis of the Obesity-Related Attenuation in the Left Dorsolateral Prefrontal Cortex Response to a Satiating Meal Using Gyral Regions-of-Interest
Journal of the American College of Nutrition, 2009, 28, 667-673
2.732Citations (PDF)
264Neural correlates of heart rate variability during emotion
NeuroImage, 2009, 44, 213-222
4.4649Citations (PDF)
265Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)
NeuroImage, 2009, 45, 1107-1116
4.4278Citations (PDF)
266Linking functional and structural brain images with multivariate network analyses: A novel application of the partial least square method
NeuroImage, 2009, 47, 602-610
4.473Citations (PDF)
267Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects
NeuroImage, 2009, 48, 668-681
4.4142Citations (PDF)
268Peripheral delivery of a ROCK inhibitor improves learning and working memory.
Behavioral Neuroscience, 2009, 123, 218-223
1.092Citations (PDF)
269A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease
Pharmacogenomics Journal, 2009, 10, 375-384
2.7372Citations (PDF)
270FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice
International Journal of Developmental Neuroscience, 2008, 26, 253-258
1.529Citations (PDF)
271Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions
NeuroImage, 2008, 40, 1214-1221
4.430Citations (PDF)
272Association between trait emotional awareness and dorsal anterior cingulate activity during emotion is arousal-dependent
NeuroImage, 2008, 41, 648-655
4.4151Citations (PDF)
273Multicenter Standardized 18 F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias
Journal of Nuclear Medicine, 2008, 49, 390-398
5.5705Citations (PDF)
274Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons
Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4441-4446
7.5589Citations (PDF)
275Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set
Physiological Genomics, 2008, 33, 240-256
2.5301Citations (PDF)
276Correlating Cerebral Hypometabolism With Future Memory Decline in Subsequent Converters to Amnestic Pre–Mild Cognitive Impairment
Archives of Neurology, 2008, 65,
6.894Citations (PDF)
277Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain
Physiological Genomics, 2007, 28, 311-322
2.5338Citations (PDF)
278Cognitive Performance in Older Women Relative to ApoE-ε4 Genotype and Aerobic Fitness
Medicine and Science in Sports and Exercise, 2007, 39, 199-207
0.8108Citations (PDF)
279Cognitive Domain Decline in Healthy Apolipoprotein E ε4 Homozygotes Before the Diagnosis of Mild Cognitive Impairment
Archives of Neurology, 2007, 64, 1306
6.8142Citations (PDF)
280Correlations Between Apolipoprotein E ε4 Gene Dose and Whole Brain Atrophy Rates
American Journal of Psychiatry, 2007, 164, 916-921
8.8108Citations (PDF)
281Relationships between plasma leptin concentrations and human brain structure: A voxel-based morphometric study
Neuroscience Letters, 2007, 412, 248-253
1.975Citations (PDF)
282Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans
NeuroImage, 2007, 35, 511-517
4.4121Citations (PDF)
283Identification of the Genetic Basis for Complex Disorders by Use of Pooling-Based Genomewide Single-Nucleotide–Polymorphism Association Studies
American Journal of Human Genetics, 2007, 80, 126-139
6.5139Citations (PDF)
284Calmodulin-binding transcription activator 1 ( CAMTA1 ) alleles predispose human episodic memory performance
Human Molecular Genetics, 2007, 16, 1469-1477
2.975Citations (PDF)
285Less activation in the left dorsolateral prefrontal cortex in the reanalysis of the response to a meal in obese than in lean women and its association with successful weight loss
American Journal of Clinical Nutrition, 2007, 86, 573-579
4.7120Citations (PDF)
286A survey of genetic human cortical gene expression
Nature Genetics, 2007, 39, 1494-1499
25.2499Citations (PDF)
287Linking Brain Imaging and Genomics in the Study of Alzheimer's Disease and Aging
Annals of the New York Academy of Sciences, 2007, 1097, 94-113
4.034Citations (PDF)
288A High-Density Whole-Genome Association Study Reveals That APOE Is the Major Susceptibility Gene for Sporadic Late-Onset Alzheimer's Disease
Journal of Clinical Psychiatry, 2007, 68, 613-618
1.8513Citations (PDF)
289Focus on Alzheimer's Disease and Related Disorders: Clinical Trials and Tribulations
Journal of Clinical Psychiatry, 2007, 68, 428-429
1.80Citations (PDF)
290The Role of Biomarkers in Clinical Trials for Alzheimer Disease
Alzheimer Disease and Associated Disorders, 2006, 20, 6-15
1.3216Citations (PDF)
291Network analysis of single-subject fMRI during a finger opposition task
NeuroImage, 2006, 32, 325-332
4.437Citations (PDF)
292Brain abnormalities in human obesity: A voxel-based morphometric study
NeuroImage, 2006, 31, 1419-1425
4.4485Citations (PDF)
293Quantitation of heteroplasmy of mtDNA sequence variants identified in a population of AD patients and controls by array-based resequencing
Mitochondrion, 2006, 6, 194-210
4.043Citations (PDF)
294Impaired platelet mitochondrial activity in Alzheimer’s disease and mild cognitive impairment
Mitochondrion, 2006, 6, 323-330
4.0160Citations (PDF)
295Gene expression correlates of neurofibrillary tangles in Alzheimer's disease
Neurobiology of Aging, 2006, 27, 1359-1371
3.4172Citations (PDF)
296A Preliminary Fluorodeoxyglucose Positron Emission Tomography Study in Healthy Adults Reporting Dream-Enactment Behavior
Sleep, 2006, 29, 927-933
0.951Citations (PDF)
297Less activation of the left dorsolateral prefrontal cortex in response to a meal: a feature of obesity
American Journal of Clinical Nutrition, 2006, 84, 725-731
4.7160Citations (PDF)
298Preliminary demonstration of an allelic association of the IREB2 gene with Alzheimer's disease
Journal of Alzheimer's Disease, 2006, 9, 225-233
2.622Citations (PDF)
299Nonprogressive transgene-related callosal and hippocampal changes in PDAPP mice
NeuroReport, 2006, 17, 829-832
1.519Citations (PDF)
300Regional network of magnetic resonance imaging gray matter volume in healthy aging
NeuroReport, 2006, 17, 951-956
1.582Citations (PDF)
301Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice
Brain Research, 2006, 1116, 194-200
2.537Citations (PDF)
302Arithmetic processing in the brain shaped by cultures
Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10775-10780
7.5321Citations (PDF)
303Genetics, Transcriptomics, and Proteomics of Alzheimers Disease
Journal of Clinical Psychiatry, 2006, 67, 652-670
1.899Citations (PDF)
304Focus on Alzheimer's Disease and Related Disorders
Journal of Clinical Psychiatry, 2006, 67, 1782-1783
1.83Citations (PDF)
305Alzheimer's Disease A Century Later
Journal of Clinical Psychiatry, 2006, 67, 1784-1800
1.8109Citations (PDF)
306Cerebral asymmetry in children when reading Chinese characters
Cognitive Brain Research, 2005, 24, 206-214
4.039Citations (PDF)
307Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism
Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8299-8302
7.5383Citations (PDF)
308Role of biomarkers in studies of presymptomatic Alzheimer's disease
2005, 1, 145-151
24Citations (PDF)
309Sensory experience of food and obesity: a positron emission tomography study of the brain regions affected by tasting a liquid meal after a prolonged fast
NeuroImage, 2005, 24, 436-443
4.4144Citations (PDF)
310Focus on Alzheimer's Disease and Related Disorders
Journal of Clinical Psychiatry, 2005, 66, 816-817
1.87Citations (PDF)
311The Differential Benefits Of Aerobic Fitness For Cognitive Performance As A Function Of ApoE Genotype
Medicine and Science in Sports and Exercise, 2005, 37, S462-S463
0.81Citations (PDF)
312Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 284-289
7.5951Citations (PDF)
313An automated algorithm for the computation of brain volume change from sequential MRIs using an iterative principal component analysis and its evaluation for the assessment of whole-brain atrophy rates in patients with probable Alzheimer's disease
NeuroImage, 2004, 22, 134-143
4.448Citations (PDF)
314Clustering huge data sets for parametric PET imaging
BioSystems, 2003, 71, 81-92
1.665Citations (PDF)
315Apolipoprotein E ε4 affects new learning in cognitively normal individuals at risk for Alzheimer’s disease
Neurobiology of Aging, 2003, 24, 947-952
3.466Citations (PDF)
316Monte-Carlo based neuroimaging set-level multiple-comparison correction
IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2003, 36, 11-15
0.35Citations (PDF)
317Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies
American Journal of Psychiatry, 2002, 159, 738-745
8.8497Citations (PDF)
318Tasting a liquid meal after a prolonged fast is associated with preferential activation of the left hemisphere
NeuroReport, 2002, 13, 1141-1145
1.539Citations (PDF)
319Sex differences in the human brain’s response to hunger and satiation
American Journal of Clinical Nutrition, 2002, 75, 1017-1022
4.7126Citations (PDF)
320A Distinctive Interaction Between Memory and Chronic Daytime Somnolence in Asymptomatic APOE e4 Homozygotes
Sleep, 2002, 25, 437-443
0.930Citations (PDF)
321Apolipoprotein E and Intellectual Achievement
Journal of the American Geriatrics Society, 2002, 50, 49-54
2.913Citations (PDF)
322Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study
Journal of the Neurological Sciences, 2001, 189, 93-98
2.158Citations (PDF)
323Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease
NeuroReport, 2001, 12, 2375-2379
1.564Citations (PDF)
324Effect of Satiation on Brain Activity in Obese and Lean Women
Obesity, 2001, 9, 676-684
4.1187Citations (PDF)
325Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease
Clinical Neuroscience Research, 2001, 1, 194-206
1.026Citations (PDF)
326Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease
Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 3334-3339
7.5472Citations (PDF)
327Tracking Alzheimerʼs disease in transgenic mice using fluorodeoxyglucose autoradiography
NeuroReport, 2000, 11, 987-991
1.563Citations (PDF)
328Thermosensory activation of insular cortex
Nature Neuroscience, 2000, 3, 184-190
17.0958Citations (PDF)
329Talkativeness in Cognitively Normal Women at Genetic Risk for Alzheimer’s Disease
Aging, Neuropsychology, and Cognition, 2000, 7, 217-226
1.63Citations (PDF)
330Regions of the human brain affected during a liquid-meal taste perception in the fasting state: a positron emission tomography study
American Journal of Clinical Nutrition, 1999, 70, 806-810
4.776Citations (PDF)
331Medial temporal lobe activation during episodic encoding and retrieval: A PET study
1999, 9, 575-581
57Citations (PDF)
332Alzheimer’s disease
Maturitas, 1999, 31, 185-200
2.922Citations (PDF)
333Neural Correlates of Levels of Emotional Awareness: Evidence of an Interaction between Emotion and Attention in the Anterior Cingulate Cortex
Journal of Cognitive Neuroscience, 1998, 10, 525-535
2.2686Citations (PDF)
334Noninvasive Quantification of the Cerebral Metabolic Rate for Glucose Using Positron Emission Tomography, 18F-Fluoro-2-Deoxyglucose, the Patlak Method, and an Image-Derived Input Function
Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 716-723
4.7296Citations (PDF)
335Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease
Annals of Neurology, 1998, 44, 288-291
6.6265Citations (PDF)
336Neuroanatomical correlates of externally and internally generated human emotion
American Journal of Psychiatry, 1997, 154, 918-925
8.8678Citations (PDF)
337Effects of size and orientation change on hippocampal activation during episodic recognition
NeuroReport, 1997, 8, 3993-3998
1.541Citations (PDF)
338Neuroanatomical correlates of pleasant and unpleasant emotion
Neuropsychologia, 1997, 35, 1437-1444
1.7792Citations (PDF)
339Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the ε4 Allele for Apolipoprotein E
New England Journal of Medicine, 1996, 334, 752-758
34.61,390Citations (PDF)
340Neuroanatomical Correlates of Veridical and Illusory Recognition Memory: Evidence from Positron Emission Tomography
Neuron, 1996, 17, 267-274
11.0261Citations (PDF)
341Functional imaging of an illusion of pain
Nature, 1996, 384, 258-260
37.9559Citations (PDF)
342The application of positron emission tomography to the study of the normal menstrual cycle
Human Reproduction, 1996, 11, 2799-2805
1.083Citations (PDF)
343Brain regions associated with retrieval of structurally coherent visual information
Nature, 1995, 376, 587-590
37.9280Citations (PDF)
344Enhanced Detection of Focal Brain Responses Using Intersubject Averaging and Change-Distribution Analysis of Subtracted PET Images
Journal of Cerebral Blood Flow and Metabolism, 1988, 8, 642-653
4.7478Citations (PDF)
345A focal brain abnormality in panic disorder, a severe form of anxiety
Nature, 1984, 310, 683-685
37.9330Citations (PDF)
346Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer\'s Related Pathological Changes in Down Syndrome
0, s7,
8Citations (PDF)
347Single- versus two-test criteria for cognitive impairment: associations with CSF and imaging markers in former American football players
Clinical Neuropsychologist, 0, 39, 2327-2351
2.72Citations (PDF)
348Dispersion-based cognitive intra-individual variability in former American football players: Association with traumatic encephalopathy syndrome, repetitive head impacts, and biomarkers
Clinical Neuropsychologist, 0, 39, 2295-2326
2.72Citations (PDF)
349Contribution of local amyloid-β and tau burden to hypometabolism in autosomal-dominant Alzheimer’s disease
Brain Communications, 0, 8,
3.60Citations (PDF)
350Alterations in CSF Amyloid-β and Tau Biomarkers in Former College and Professional American Football Players: Findings from the DIAGNOSE CTE Research Project
Journal of Neurotrauma, 0, ,
3.60Citations (PDF)